Article info

PDF

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
  1. R Fleischmann, University of Texas Southwestern Medical Center, 5939 Harry Hines Blvd., Dallas, Texas 75235, USA; rfleischmann{at}arthdocs.com
View Full Text

Citation

Fleischmann R, Vencovsky J, van Vollenhoven RF, et al
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

Publication history

  • Accepted October 29, 2008
  • First published November 17, 2008.
Online issue publication 
May 12, 2009

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.